The purpose of this research study is to assess the response rate of the investigational drug BMS-247550 (Ixabepilone) in women with metastatic breast cancer who are refractory to an anthracycline, a taxane, and capecitabine.

Inclusion Criteria:

• Patients must have received all 3 drugs- an anthracycline, taxane, and capecitabine (alone or in combination) and be resistant
• No more than 3 prior chemotherapy regimens in the metastatic setting
• Must have at least one target lesion that is radiographically measurable
• Good performance status
• No history of or current brain or leptomeningeal disease